These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2149312)

  • 21. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
    Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experiences with solcoseryl in treatment of stage II peripheral arterial occlusive disease--assessment of clinical effectiveness].
    Horsch S; Claeys L
    Vasa Suppl; 1992; 35():151-2. PubMed ID: 1481024
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group.
    Int Angiol; 1996 Mar; 15(1):75-80. PubMed ID: 8739541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
    Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
    Rudofsky G; Haussler KF; Künkel HP; Schneider-May H; Spengel F; Symann O; Werner HJ; Rössner M
    Vasa Suppl; 1987; 20():375-8. PubMed ID: 3321494
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of controlled vascular training on the pain free walking distance and plasmaviscosity in patients suffering from peripheral arterial occlusive disease.
    Häfner HM; Jünger I; Geyer A; Jünger M; Strölin A
    Clin Hemorheol Microcirc; 2009; 41(1):73-80. PubMed ID: 19136745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
    Spitzer S; Bach R; Schieffer H
    Int Angiol; 1992; 11(3):204-10. PubMed ID: 1460355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
    Rudofsky G
    Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K; Rogatti W; Rüttgerodt K
    Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of trophic ulcers of the lower extremities with Trental-400].
    Koshkin VM; Bogdanets LI; Makarova LD
    Khirurgiia (Mosk); 1996; (1):49-51. PubMed ID: 8683922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Controlled vascular training in IIb peripheral arterial occlusive disease: additive effect of intravenous PGE1 versus intravenous pentoxifylline during training].
    Scheffler P; de la Hamette D; Müller H
    Vasa Suppl; 1991; 33():350-2. PubMed ID: 1788754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Peripheral macro-and microcirculatory changes in acute arterial obstruction with papaverine and trental administration].
    Koshkin VM; Adil'khanov SG; Antonova NIu
    Vestn Khir Im I I Grek; 1979 Dec; 123(12):56-60. PubMed ID: 524688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease.
    Hildebrand M; Krause W; Oberender HA; Zurdel-Dillinger S; Jünger M; Bodenburg H
    Eicosanoids; 1990; 3(3):145-8. PubMed ID: 1700723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl].
    Kling H
    Fortschr Med; 1979 May; 97(19):926-8. PubMed ID: 109382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience with pentoxifylline in chronic obliterative disease of the leg arteries in hospitalized and ambulatory patients].
    Sondern W; Leube G
    Med Welt; 1979 Sep; 30(37):1367-9. PubMed ID: 502814
    [No Abstract]   [Full Text] [Related]  

  • 37. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E; Pancera P; Zannoni M; Arcaro G; Priante F; Lechi A
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The use of pentoxyphylline in the treatment of patients with chronic obliterative diseases of lower limb arteries].
    Koshkin VM
    Angiol Sosud Khir; 2005; 11(4):141-7. PubMed ID: 16474301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin].
    Mollo P
    Clin Ter; 1991 Apr; 137(2):113-5. PubMed ID: 1828404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A; De Martini D; Flore R; Gaetani E; Gasbarrini A; Gerardino L; Pola R; Santoliquido A; Serricchio M; Tondi P; Nolfe G
    Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.